News

Credo Technology Shines with Strong Results and Key Partnerships

Credo Technology Shines with Strong Results and Key Partnerships

Credo Technology Group Reports Record Earnings

Credo Technology Group (NASDAQ: CRDO) recently announced its third-quarter earnings, highlighting a remarkable performance. The company reported earnings of 25 cents per share, surpassing analysts' expectations of 18 cents per share. This impressive performance showcases Credo's growth trajectory in a competitive market.

Revenue Surges and Future Expectations

The quarterly revenue reached $135 million, a significant jump from $53.05 million reported a year earlier. This outperformance compared to the predicted $120.06 million demonstrates Credo’s robust operational strategies and increasing demand for its innovative solutions.

Looking ahead, Credo anticipates fourth-quarter revenue ranging from $155 million to $165 million, well above the consensus estimate of $137.43 million. This optimistic outlook solidifies investor confidence in Credo's capabilities.

Analysts Adjust Their Ratings

In response to these strong results, several Wall Street analysts have revised their ratings for Credo. Needham's analyst, Quinn Bolton, reiterated a Buy rating with a price target of $80. Roth MKM's Sujeeva De Silva also maintained a Buy rating, supported by the strong revenue projections. On the other hand, Christopher Rolland from Susquehanna set a Neutral rating, adjusting his price target from $80 down to $60.

Driving Factors Behind the Growth

Notably, a significant portion of Credo's revenue has been attributed to its relationship with Amazon.com Inc (NASDAQ: AMZN), which accounted for a staggering 86% of the revenue in the third quarter, marking a 388% increase quarter-over-quarter. This partnership with a leading hyperscaler is a pivotal element driving Credo’s financial outlook.

Management anticipates that revenue from Amazon will remain strong into the next quarter, while they also expect other customers to contribute approximately 33% of total revenue. This diversification is poised to enhance Credo's business resilience in the evolving tech landscape.

Innovations and Future Growth

Credo continues to innovate, exemplified by its PCIe retimer product line, which received certification from PCIe SIG. This critical approval positions the company to enter an ODM AI platform commitment, with expectations of revenue streams materializing in 2026. This strategic move into high-tech markets signals Credo’s aim to remain competitive and relevant in the fast-paced AI industry.

Market Dynamics and Competitive Landscape

Bolton further emphasized the unprecedented growth from Amazon, raising his shipment estimates significantly for fiscal years 2026 and 2027. The company's broader strategy includes cultivating a more diverse customer base, with an expectation that 3-4 clients may reach the 10% sales threshold in future quarters.

Currently, Credo is ramping AECs with three key hyperscalers—Microsoft Corp (NASDAQ: MSFT), Amazon, and xAI. Additionally, they are pursuing qualifications with two more hyperscalers expected to ramp up in fiscal 2026, indicating a solid growth path and relationship-building within the tech community.

Conclusion and Stock Performance

Despite the positive trajectory, recent price action indicates a dip in CRDO stock, which was down 15.4% to $45.87. The market reaction reflects broader market pressures rather than just company performance, as analysts are optimistic about Credo's potential and future collaborations.

Frequently Asked Questions

What were Credo Technology's earnings this quarter?

Credo Technology reported earnings of 25 cents per share, exceeding analyst estimates.

How much revenue did Credo generate in the last quarter?

Credo generated $135 million in revenue this past quarter, significantly up from $53.05 million a year ago.

Who are Credo's major customers?

One of Credo's largest customers is Amazon, which accounted for 86% of its revenue in the last quarter.

What is the future revenue projection for Credo?

Credo anticipates its fourth-quarter revenue will be between $155 million and $165 million.

Who are the analysts covering Credo Technology?

Analysts from Needham, Roth MKM, and Susquehanna have recently issued ratings on Credo’s stock.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 87

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
O-I Glass Faces Class Action: Investor Implications

Updated Category News Views 68

O-I Glass in Hot Water Over Misleading Statements I'll tell you, nothing gets my goat quite like uncovering deceptive practices in the corporate world. It seems O-I Glass, Inc. (NYSE: OI), might have played a fast one with its shareholders. The company is staring down the barrel of a class action lawsuit from Schall, Brown & Schwartz LLP, alleging they weren't entirely...

Continue Reading
KT&G Launches Heated Tobacco in Kazakhstan's Market

Updated Category News Views 43

KT&G Lights Up Kazakhstan In a bold move, KT&G is laying down the gauntlet in Kazakhstan's tobacco market, introducing its cutting-edge heated tobacco gizmo and a handful of sleek FAIIM sticks. Launching this October, these aren't just any devices—they're the FLEX locals have been waiting for, rebranded from South Korea's lil AIBLE and AIIM but made to fit right in with...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 178

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 730

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 323

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 226

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Niagara Networks Boosts TLS 1.3 Decryption to 90+ Gbps

Updated Category News Views 73

In a digital era where encryption is racing ahead like a runaway train, Niagara Networks has stepped up with some serious muscle enhancements to their ePacketron platform. They're not just playing catch-up with the latest TLS 1.3 decryption capabilities; they're leading the charge with a robust over 90 Gbps performance—no small feat in today's encrypted traffic...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 490

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 228

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
aria-label="Continue reading: JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer"> Continue Reading